A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients.
Francis G. LeVeque(Fred Hutch Cancer Center), Charles C. Muscoplat(Utah State University), D Potter(Harper University Hospital), M B Zimmer(Harper University Hospital), Margaret A. Montgomery(Harper University Hospital), Barry W. Steiger(Harper University Hospital), John W. Rieke(Harper University Hospital), Susan C. Gallagher
Cited by 292
Related Papers
Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation
|Journal of Clinical Oncology|2001|682
Oral Pilocarpine for Post-Irradiation Xerostomia in Patients with Head and Neck Cancer
|New England Journal of Medicine|1993|483
Oral pilocarpine for radiation-induced xerostomia: Integrated efficacy and safety results from two prospective randomized clinical trials
|International Journal of Radiation Oncology*Biology*Physics|1995|139